During endochondral bone development, osteoblasts are continuously differentiated from locally residing progenitor cells. However, the regulation of such endogenous osteoprogenitor cells is still poorly understood mainly due to the difficulty in identifying such cells in vivo. In this paper, we genetically labeled different cell populations of the osteoblast linage using stagespecific, tamoxifen-inducible Cre transgenic mice to investigate their responses to a proliferative stimulus. We have found that overactivation of Kras signaling in type II collagen-positive, immature osteoprogenitor cells, but not in mature osteoblasts, substantially increases the number of their descendant stromal cells and mature osteoblasts, and subsequently increases bone mass. This effect was mediated by both, the extracellular signal-regulated kinase (ERK) and phosphoinositide 3 kinase (PI3K), pathways. Thus we demonstrate that Ras signaling stimulates proliferation of immature osteoprogenitor cells to increase the number of their osteoblastic descendants in a cell-autonomous fashion.
Bones are formed and maintained by multiple types of bone cells. 1 Mineralized bone matrix is produced by osteoblasts. Osteoblasts produce a large amount of bone matrix proteins including type I collagen and osteocalcin. Osteoblasts then die or further differentiate into osteocytes that are embedded in the bone matrix. 2, 3 Bone is constantly remodeled throughout life. During this process, osteoblasts are continuously differentiated from locally residing mesenchymal progenitor cells. Thus, proliferation and differentiation of the osteoblast progenitors need to be well coordinated to maintain adequate bone mass and function.
However, characteristics, kinetics and regulation of such endogenous osteoprogenitor cells are still poorly understood, primarily due to the lack of proper tools for in vivo analysis of such cells.
Recently, it has been shown that a subset of early osteoprogenitor cells show a promoter activity of the type II collagen gene (Col2a1); a lineage tracing study using Col2-creER and Cre reporter transgenic mice in which tamoxifen injection genetically labels Col2-positive cells shows that Col2-positive cells include self-renewing early osteoprogenitor cells. 4 Upon lineage commitment, osteoprogenitor cells start expressing Sp7 (Osterix; Osx). [3] [4] [5] In contrast, mature osteoblasts and their descendants can be exclusively labeled by the use of short promoter fragments of the type I collagen gene (Col1a1). 3, 6 In this study, using stage-specific, tamoxifen-inducible Cre transgenic lines, we demonstrate that Ras signaling regulates proliferation of Col2-positive osteoprogenitor cells and controls bone mass, whereas Ras overactivation shows little effect in mature osteoblasts. Thus, the difference of responsiveness to Ras signaling discriminates differentiation stages of cells of the osteoblast lineage.
Results
Col2-positive cells are self-renewing osteoprogenitors.
To determine the fate of osteoblast-lineage cells in different differentiation stages, we genetically labeled cells using stage-specific, tamoxifen-inducible Cre transgenic mice and R26R-tdTomato Cre reporter mice. We crossed R26R-tdTomato reporter mice 7 with Cre transgenic mice expressing tamoxifen-inducible Cre recombinase driven by a type II collagen (Col2a1) promoter (Col2-creER), 8 an osterix (Sp7; Osx) promoter (Osx-creER), 9 or a 3.2 kb-long type I collagen promoter (Col1-creER) 9 (Figure 1a ). We injected a single dose of tamoxifen into pregnant mothers at E18.5 to label Cre-expressing cells. Tamoxifen induces Cre recombination and subsequently tomato expression, and thus Cre-expressing cells as of tamoxifen injection and their descendants will express tomato red fluorescent protein.
As recently shown in postnatal mice, 4 a small number of Col2-creER-expressing (Col2-positive) cells were labeled in the bone marrow 2 days after tamoxifen injection (Figures 1b and e, Supplementary Figures S1A, S1D). Over time, these cells produced a significant number of descendants that differentiated into bone stromal cells, osteoblasts and osteocytes (Figures 1c,d and f-h, Supplementary Figures S1B, S1C, S1E, S1F).
As expected, Osx-creER-expressing (Osx-positive) and Col1-creER-expressing (Col1-positive) cells were abundantly present on bone surface at early time points after tamoxifen injection. In these models, numbers and localization patterns of RFP-labeled cells appeared relatively constant during the 1-month chase period (Figures 1i-n, Supplementary Figures S1G-S1N). Col1-creER-expressing cells and their descendants are mainly osteoblasts and osteocytes (Figure 1n , Supplementary Figure S1N ), whereas Osx-creER labels stromal cells, osteoblasts and osteocytes (Figure 1k , Supplementary Figure S1J ). Tamoxifen injection into Osx-creER at E18.5 does not label cells in the secondary ossification center (Supplementary Figure S1H ). Because the secondary ossification center is not yet formed at E18.5, this finding suggests that Osx-positive cells and their descendants in the primary ossification center unlikely migrate into the secondary ossification center to serve as a source of osteoblasts.
Expression of an oncogenic Kras in Col2-positive cells increases the number of their descendant cells and trabecular bone mass. Mechanisms that regulate proliferation, differentiation and maintenance of endogenous osteoprogenitor cells in bone are still largely unknown. The recent finding that a self-renewing endogenous osteoprogenitor population can be genetically labeled using Col2-creER and R26R-tdTomato transgenic mice provided an opportunity to investigate the regulation of osteoprogenitor cells in vivo.
One of major regulators of cell proliferation is the Ras signaling pathway. The small GTPase, Ras, mediates the extracellular proliferative stimuli to downstream intracellular signaling molecules, including the extracellular signalregulated kinase (ERK) and phosphoinositide 3 kinase (PI3K) pathways, to stimulate cell cycle progression. Thus, we hypothesized that Ras-mediated signaling pathways might regulate osteoprogenitor cell proliferation.
In order to study the effect of overactivation of Ras signaling in osteoprogenitor cells in vivo, we expressed an active form of Kras (Kras G12D ) 10 in Col2-positive cells that were simultaneously labeled with Tomato red fluorescent protein using Col2-creER transgenic mice. Expression of Kras G12D and Tomato was induced at E18.5 by a single dose of tamoxifen injection into pregnant mothers.
Two days after tamoxifen injection, only small numbers of Tomato-expressing cells were found in the metaphyseal region of both Kras G12D -positive and negative mice (Figures 2a-d ). However, 1 month later Tomato-positive cells were significantly more abundant in Kras G12D -positive mice than in Kras G12D -negative mice (Figures 2e and f) . The increase in Tomato-positive cells in Kras G12D -positive mice involved osteocytes, osteoblasts as well as stromal cells (Figures 2g and h). Hematoxylin-eosin (H/E) staining of tibia sections showed a striking increase in trabecular bone mass in mice with Kras activation in Col2-positive cells and their descendants (Figures 2i and j). Littermates lacking Cre or Kras were used as controls, and they received the same amount of tamoxifen as the mutant mice. Kras G12D mice without Cre recombination had the same bone phenotype as wild-type mice. In the absence of tamoxifen there were no overt bone phenotypes in mutant mice (Supplementary Figures  S2A-S2B ).
A similar phenotype was observed in the humerus as in the tibia upon Kras activation in Col2-postive cells (Supplementary Figures S2C-S2D). Microcomputed tomography (μCT) analysis showed that there was a significant increase in the bone volume fraction, trabecular number and trabecular thickness and a decrease in trabecular separation (Figures 2k-p) . The cortical bone parameters were unchanged. There were no overt changes in tartrate-resistant acid phosphatase (TRAP) staining ( Supplementary  Figures S2I-S2J ), suggesting that bone-resorbing osteoclasts were not affected.
In addition to the increased bone mass, H/E staining revealed a substantial increase in the number of stromal cells between the trabeculae ( To assess the proliferation of stromal cells, BrdU assay was performed. As expected, the BrdU labeling index of the stromal cell population in the Kras G12D mouse was increased at postnatal day P10 (Figures 3m-q).
Overactivation of Ras signaling influences cell survival. In order to test whether oncogenic Ras expression affects cell survival, a cell death assay (TUNEL assay) was performed to compare the apoptosis rate in the primary spongiosa of Kras G12D mice and wild-type mice (Supplementary Figures  S3E-S3G ). Although a tendency for increased apoptosis in Kras G12D mice was observed, the difference in cell death signals counted was not statistically significant (control versus mutant: 11 ± 4.6 versus 19.7 ± 4 P = 0.07, n = 3 each). This suggests that the increase in proliferation of stromal cells is the dominant mechanism for bone increase in the Kras G12D mice.
We then wanted to address the question whether the effect of Kras overexpression in Col2-positive cells was age-specific. Activating Kras at P20 in Col2-positive cells caused a similar increase in bone and stromal cells, suggesting that Col2-positive cells are continuously present and serve as MAPK and PI3K are the main signaling pathways responsible for the increase in bone with Kras activation. Kras signals mainly through the mitogen-activated protein kinase (MAPK) and PI3K pathways. 11 In order to investigate whether activation of these signaling pathways was responsible for the bone phenotype of Kras mice, we pharmacologically inhibited the ERK and PI3K pathways. We injected U0126, an inhibitor of ERK kinase (MEK), or LY294002, a PI3K inhibitor from E18.5 through P21. Both Supplementary Figures S4A-S4F) . These findings suggest that activation of both MAPK and PI3K pathways contribute to the bone phenotype of Kras G12D mice. Kras G12D expression in Col1-positive cells does not increase stromal cells or bone mass. Next, we investigated the effect of Kras activation in lineage-committed osteoblasts. We used Osx-creER and Col1-creER to target osteoblasts in early and late differentiation stages, respectively. A single dose of tamoxifen was injected into mice at E18.5 to induce expression of Kras G12D and Tomato in Osx-positive or Col1-positive cells. Kras G12D expression in Osx-positive cells caused a phenotype similar to, but somewhat milder than, that of the Col2-creER model (Figures 5a-d) . Tomato-positive Osx-positive cells and their descendants were found in both bone and stromal compartments (Figures 5e-h) .
In contrast, activating Kras in the Col1-positive cells caused no significant changes in bone or stromal cells at P28 (Figures 5i-l) , despite that Kras G12D expression significantly increased ERK phosphorylation in osteoblasts ( Supplementary Figures S5A-S5D ). Consistent with this result, there was no significant increase in tomato-positive Col1-positive cell descendants (Figures 5m-p) . These results suggest that Ras activation has no stimulatory effect in differentiated osteoblasts.
Discussion
In this study, we investigated the role of Ras signaling in three different cell populations of the osteoblast lineage, that is, Col2-, Osx-and Col1-positive cells, during bone development.
Kras overactivation in Col2-positive or Osx-positive cells in bone at E18.5 led to a significant increase in number of their descendant cells and trabecular bone mass. In contrast, Kras overactivation in Col1-positive cells did not show significant effects in cell number or bone mass, suggesting that Col2-and Osx-positive cells, but not Col1-positive cells, include proliferative osteoblast progenitors. This study also demonstrates that Ras signaling is an important positive regulator of proliferation of early osteoprogenitor cells.
Multiple signaling molecules, including receptor tyrosine kinases (RTKs), 12 have been implicated in regulation of proliferation and survival of bone progenitor cells. 13, 14 Kras, a small GTPase activated by RTKs, triggers downstream effector pathways, such as the MAPK (mitogen-activating protein kinase), PI3K (Phosphatidylinositol 3'-kinase) and Ral-GEF (Ras-like small GTPases) pathways, to regulate cellular functions including proliferation, differentiation and apoptosis. 15 Multiple Rasactivating molecules, including fibroblast growth factors (FGFs)/ FGF receptors, 16 epidermal growth factors (EGFs)/ EGF receptors 17 and insulin-like growth factors (IGFs) and their receptors, 18 have been implicated in regulating bone development. Ras signaling has been shown to increase stem/progenitor cell proliferation in multiple tissues. Kras activation has been shown to increase proliferation of bone marrow hematopoietic cells. [19] [20] [21] Additionally an oncogenic Kras increases proliferation of mouse embryonic fibroblasts 22 and facilitates selfrenewal of a subtype of alveolar stem cells. 23 Additionally Ras activation by partial loss of Nf1 gene in osteoprogenitor cells was found to increase proliferation and cause premature apoptosis. 24 In the present model apoptosis was not found significantly increased; thus, we conclude that the increase in proliferation is the dominant effect of Kras activation in osteoprogenitor cells.
However, there have been relatively limited studies that investigate the role of Ras-MAPK signaling pathway in osteoblast progenitor cells in bone in vivo. It has been shown that the ERK signaling pathway, a major downstream mediator of Ras, in mesenchymal progenitor cells promotes osteoblast differentiation and bone formation during early skeletal development. 25 Nonetheless, the proliferative effect of ERK signaling specifically in osteoprogenitor cells has not been addressed. In another study in which a dominant negative or a constitutively active MEK1 was expressed in relatively mature osteoblasts, ERK signaling stimulated osteoblast differentiation without obvious changes in proliferation. 26 The result of this study is consistent with our finding that Kras overactivation in Col1-positive mature osteoblasts had little effect in bone mass or stromal cell proliferation. In our study, we found that ERK inhibition significantly reduced the number of stromal cells in Kras G12D mice, suggesting that ERK overactivation is, at least in part, responsible for the proliferative effect of Kras G12D expression in Col2-positive osteoprogenitors. We also found that PI3K inhibition partially reduced stromal cells and partially rescued the bone phenotype caused by Kras G12D expression. Thus our study demonstrates that in addition to the ERK pathway, the PI3K pathway also plays an important role in osteoprogenitor proliferation.
To investigate the pathways downstream of Kras we injected mice with small molecule inhibitors of MEK and PI3K. With the dosage and timeframe of these experiments we did not observe significant changes in the mouse body size or condition. The wild-type control mice injected with MEK inhibitor showed no appreciable changes in bone.
Over-expression of active Kras in Col2-Cre-positive cells is not physiologically present during development, and therefore our findings do not necessarily demonstrate that endogenous Ras signaling is a physiologic regulator of osteoprogenitor cells. Nevertheless, using this system, we are able to show that Col2-positive or Osx-positive cells, but not Col1-positive cells include osteoprogenitor cells that can be discriminated by responses to Ras signaling. Additionally these experiments show that MAPK and PI3K pathways activation in the above cell populations can activate bone formation.
The loss of balance between bone formation and bone resorption results in osteoporosis. 27 Since treatment options to increase bone formation are currently limited, 28 novel bone anabolic therapies are highly desired. Our study shows that stimulating Ras signaling in endogenous osteoprogenitor cells can be a valid treatment strategy for osteoporosis.
Materials and Methods
Mice. Col2a1-creERT2, 8 Osx-creERT2, 3 Col1-creERT2, 9 and Cre-dependent Kras transgenic, loxP-stop-loxP-Kras G12D10 mice have been described elsewhere. The Cre reporter, Rosa26-loxP-stop-loxP-tdTomato mice were acquired from Jackson Laboratory (Bar Harbor, ME, USA). 7 All procedures were conducted in compliance with the Guideline for the Care and Use of Laboratory Animals approved by Massachusetts General Hospital's Institutional Animal Care and Use Committee (IACUC). Mice were in a mixed genetic background. Comparisons were made between littermates. Tamoxifen injections were given i.p. at a dose of 0.1 mg/ g to pregnant females as described elsewhere. 4 Histology. For histological analysis mice were dissected, fixed in 10% formalin overnight and decalcified in 10% EDTA for a period ranging from 1 to 14 days, depending on the age of the mice. For H/E staining, BrdU staining, immunohistochemistry and in situ hybridization, samples were paraffin processed and cut. For fluorescent reporter analysis decalcified samples were cryoprotected in 30% sucrose/ phosphate buffer saline (PBS) solutions then in 30% sucrose/PBS:OCT (1:1) solutions, each overnight at 4°C. Samples were embedded in OCT compound (TissueTek, Sakura, Torrance, CA, USA) and transferred to dry ice to solidify OCT. Samples were cryosectioned at the thickness of 15 μm using a cryostat (Leica CM1850). Nikon Eclipse E800 microscope was used for imaging. Images were merged with Spot Advanced Software.
Immunohistochemistry and in situ hybridization. Immunohistochemistry analysis for phosphorylated ERK (phospho-ERK) was performed as previously described using the Perkin Elmer TSA biotin system kit. 29 The primary antibody directed against phospho-p44/42 (ERK1/2) (Cell Signaling, Danvers, MA, USA, catalog number:#43700) was diluted 1:300 and the secondary biotinylated anti-rabbit antibody (Vector, Burlingame, CA, USA, catalog number #BA1000 ) was diluted 1:300. Anti p-Akt (Cell Signaling, catalog number #2965) antibody was diluted 1:500. ISH for type 1 collagen and osteocalcin was performed according to published protocols. 30 For all immunostaining experiments, samples from three mice per group were analyzed.
Cell proliferation assay. For BrdU labeling 50 μg of BrdU per gram of body weight was intraperitoneally injected into mice 2 h before euthanasia. BrdU was detected using the BrdU in situ staining kit (invitrogen, Waltham, MA, USA). The BrdU labeling index was calculated as the ratio of BrdU-positive nuclei over total nuclei of stromal cells of the metaphyseal tibia.
TRAP staining. Slides were deparaffinized and rehydrated. TRAP reagent consisted of 6 ml 50 mM tatrate in acetate buffer (PH 5.0), 0.5 mg Naphthol As-Mx, 50 μl N,N dimethylamide and 3 mg fast red violet LB. TRAP reagent was added for 5-10 min and once satisfactory color was observed, slides were washed with water and then with PBS. At the end the slides were mounted with water-based medium.
Cell death assay (TUNEL assay). Cell death was evaluated on sections using an in situ cell death detection kit (Roche, Branford, CT, USA) according to the manufacturer's instructions.
MicroCT analysis. A high-resolution desktop micro-tomographic imaging system (μCT40, Scanco Medical AG, Basserdorf, Switzerland) was used to assess trabecular and cortical in the proximal metaphysis and diaphysis of the tibia, respectively. Scans were acquired and analyzed as previously described. 31 Image acquisition and analysis were performed according to the JBMR guidelines for the use of μCT in rodents. 32 To assess the trabecular architecture, transverse CT slices were evaluated in a 1500 μm (150 slices) region beginning 750 μm below the proximal growth plate and extending distally. The trabecular bone region was identified by semi-manually tracing with the assistance of an auto-thresholding software algorithm. A mineral density threshold of 225 mgHA/cm 3 was used for all images to segment bone from soft tissue.
Rescue experiments-inhibitors. The MEK1 inhibitor (U0126) and the PI3K inhibitor (LY294002) were purchased from Selleckchem (Houston, TX, USA). Inhibitors were first dissolved in DMSO according to the manufacturer's instructions, then diluted into PBS, and injected daily into pregnant as well as nursing mothers intraperitoneally from E18.5 through P9.5. Subsequently, the inhibitors were injected to pups. MEK inhibitor was injected at a dose of 5 mg/kg per day. PI3K inhibitor was injected at a dose of 100 mg/kg four times a week.
